

The GOG Highlight Reel January 2025

A GOG Foundation, Inc. Educational Program

Saturday, January 18, 2025

9:30 am - 12:00 pm MST

Phoenix, Arizona





MODERATORS

Thomas Herzog, MD

University of Cincinnati Cancer Center, Cincinnati, OH

Bradley J. Monk, MD

Florida Cancer Specialists and Research Institute, West Palm Beach, FL



OUR MISSION

To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies



OUR VISION

To be the premier collaborative network for transformative research in gynecologic malignancies

FACULTY



Ramez Eskander, MD
University of California San Diego
Moore's Cancer Center
San Diego, California



Amanda Nickles Fader, MD
Johns Hopkins University
Baltimore, Maryland



Bhavana Pothuri, MD
NYU Langone
New York City, New York



Kathleen Moore, MD
University of Oklahoma
Stephenson Cancer Center
Oklahoma City, Oklahoma



David O'Malley, MD
The Ohio State University
James Cancer Center
Columbus, Ohio



Leslie Randall, MD
Inova Health
Fairfax, Virginia



Brian Slomovitz, MD
Mount Sinai Medical Center
Miami Beach, Florida



GOG Highlight Reel

GOG FOUNDATION®
Transforming the standard of care™

GOG Highlight Reel Pre-Test



LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR

Increased knowledge regarding:

- The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The key trial data for newly approved therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
- The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers

Greater competence related to:

- Understanding the available therapies and selecting treatments for women with cervical, endometrial, and ovarian cancers
- Interpret and understand the application of recent data into clinical practice
- Learn about current clinical trials in gynecologic cancers and understand what opportunities exist in the public domain

GOG FACULTY DISCLOSURE INFORMATION

The GOG Highlight Reel:
An Education Series Highlighting Newsworthy Data Distillation
and Emerging Global Therapies in Clinical Trials
January 18, 2025
Phoenix, Arizona

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.



GOG FACULTY DISCLOSURE INFORMATION

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Thomas Herzog, MD	Moderator		Astra Zeneca; Caris; Clovis; Eisai; Epsilon; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics	Scientific Advisory Boards
Bradley Monk, MD	Moderator		Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks	Consultant (Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks) Speaker (AstraZeneca; Eisai; GSK; Immunogen; Abbvie; Merck)
Speaker Disclosures				
Eskander, Ramez, MD	Speaker		AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana; Nuvectis Pharma, Merck, Loxo @ Lilly, Genmab/Seagen, Clovis Oncology, Acrivon therapeutics, Zentalis, Eisai, Gilead, Roche	Consultant (AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana) Research Funding (Nuvectis Pharma, GSK, Merck, Daiichi Sanyo, Loxo @ Lilly, AstraZeneca, Genmab/Seagen, Clovis Oncology, Acrivon therapeutics, Zentalis, Eisai, Gilead, Roche)
Kathleen Moore, MD	Speaker		Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE	Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) Travel, Accommodations, Expenses (BioNTech SE)
Amanda Nickles Fader, MD	Speaker		GSK; Up to Date; Department of Defense Ovarian Cancer Academy Grant; GOG Foundation	Honoraria (GSK; Up to Date) Research Funding (Department of Defense Ovarian Cancer Academy Grant) Other (GOG Foundation)

GOG FACULTY DISCLOSURE INFORMATION (Cont.)

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
David O'Malley, MD	Speaker		AbbVie; AdaptImmune; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; Bristol Myers Squibb; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Deciphera Pharma; Duality Bio; Eisai; Elevar; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Incyte Corporation; IOVANCE Biotherapeutics; Jazz Pharmaceuticals; Karyopharm; Laekna; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Onconova; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics (SeaGen); Sutro Biopharma; SWOG; Verastem, Inc; Vincexx Pharma; Xencor; Zentalis	Institution Received Funds for research (AbbVie; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeiGene USA, Inc.; Boston; Biomedical; Bristol Myers Squibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Incyte Corporation; IOVANCE Biotherapeutics; Karyopharm; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics (SeaGen); Sutro Biopharma; SWOG; Verastem, Inc) Ad Board/Consultant (AbbVie; AdaptImmune; Agenus, Inc.; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Jazz Pharmaceuticals; Laekna; Leap Therapeutics, Inc.; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova; Regeneron Pharmaceuticals, Inc; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincexx Pharma; Xencor; Zentalis
Bhavana Pothuri, MD, MS	Speaker		AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; Eisai; GlaxoSmithKline; GOG foundation; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries	Consultant (AstraZeneca; Eisai; GlaxoSmithKline; GOG foundation; Merck; Mersana; Seagen Inc.; Sutro) Grant/Contract (AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; GlaxoSmithKline; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries)
Leslie Randall, MD	Speaker		AstraZeneca, Clovis, GSK, Immunogen, Seagen	Honoraria (AstraZeneca, Clovis, GSK, Immunogen, Seagen)
Brian Slomovitz, MD	Speaker		Seagen; Novocure; Astrazeneca; Aadi; Regeneron; Immunocore; Merck; Gilead, Eisai; Incyte	Consultant
Holley Engbert	Staff	X		
Jill Reese	Staff	X		
Michelle N Small, MPH	Staff	X		
Angeles Alvarez-Secord, MD	Edu-Chair		AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Bio	Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio)

GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. Participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the online evaluation that will be sent to all registered participants who provide a valid email address and attend the activity. Participants who complete the educational activity and evaluation will receive a certificate of credit.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

THANK YOU

COMMERCIAL SUPPORTERS FOR INDEPENDENT MEDICAL EDUCATION SUPPORT

AbbVie

Acrivon Therapeutics

AstraZeneca

Corcept Therapeutics

GSK

EISAI



**THANK YOU TO OUR
SPONSORS**

**Pfizer/Genmab
GSK**

FACULTY



Ramez Eskander, MD
University of California San Diego
Moore's Cancer Center
San Diego, California



Amanda Nickles Fader, MD
Johns Hopkins University
Baltimore, Maryland



Bhavana Pothuri, MD
NYU Langone
New York City, New York



Kathleen Moore, MD
University of Oklahoma
Stephenson Cancer Center
Oklahoma City, Oklahoma



David O'Malley, MD
The Ohio State University
James Cancer Center
Columbus, Ohio



Leslie Randall, MD
Inova Health
Fairfax, Virginia



Brian Slomovitz, MD
Mount Sinai Medical Center
Miami Beach, Florida

AGENDA

9:30 am – 9:35 am	Welcome and Introductions
9:35 am – 10:05 am	Recent ADC Discoveries, <i>Dr. Kathleen Moore</i> <i>Interactive ADC Discussion with all faculty</i>
10:05 am – 10:25 am	Ovarian Cancer, Understanding Treatment Opportunities, <i>Dr. David O'Malley</i> <i>Interactive Discussion with all faculty</i>
10:25 am – 10:50 am	Endometrial Cancer, Approvals & Incorporating Precision Diagnostics, <i>Dr. Ramez Eskander, MD</i> <i>Interactive Discussion with all faculty</i>
10:50 am – 11:20 am	Emerging Endometrial Trials, <i>Dr. Brian Slomovitz</i> <i>Interactive Discussion with all faculty</i>
11:20 am – 11:30 am	Cervix Cancer Highlights, <i>Dr. Leslie Randall</i> <i>Interactive Discussion with all faculty</i>
11:30 am – 11:50 am	Advancing the Management of Rare Tumors, <i>Dr. Amanda Nickles Fader & Dr. Bhavana Pothuri</i> <i>Interactive Discussion with all faculty</i>
11:50 am - 12:00 pm	Closing Remarks and Announcement of the Summer 2025 GOG Highlight Reel